A research protocol for a randomised parallel study assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy has been published in the British Medical Journal, on behalf of the CLOuD Consortium.
The CLOuD study builds on recent technological advances of closed-loop insulin delivery (artificial pancreas). The purpose of this study is to test the impact of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion.
The primary objective is to evaluate the effect of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion by comparing the area under the stimulated C-peptide curve (AUC) of a mixed meal glucose tolerance test conducted at the 12-month visit in participants receiving closed-loop insulin delivery with those receiving standard therapy, i.e. multiple daily injections applying basal-bolus regimen.
Published April 22, 2020
Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.
Restoration of sight from a rare genetic mutation may now become a reality thanks to a prestigious award from the National Institute for Health Research (…
An artificial pancreas could soon help people living with type 2 diabetes and who also require kidney dialysis.